PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026New England Journal of Medicine8 citations

A Phase 3 Trial of Brepocitinib in Dermatomyositis

View Full Paper
RVRuth Ann VleugelsJPJulie J. PaikIVIazsmin Bauer Ventura

Key Points

  • To evaluate the efficacy of brepocitinib in treating adults with resistant dermatomyositis.
  • Phase 3 clinical trial design
  • Comparison of 30 mg and 15 mg doses of brepocitinib
  • Assessment using composite myositis index and skin disease severity scales
  • Analysis of glucocorticoid tapering and functional disability
  • The 30 mg dose of brepocitinib showed significant benefit over the 15 mg dose
  • Improved scores on the composite myositis index
  • Reduction in skin disease severity
  • Facilitated glucocorticoid tapering
  • Decreased functional disability levels

Abstract

In adults with dermatomyositis that was resistant to previous therapy, the use of brepocitinib at a dose of 30 mg (but not at a dose of 15 mg) resulted in significant benefits with respect to a composite myositis index, skin disease severity, glucocorticoid tapering, and functional disability. (Funded by Priovant Therapeutics; ClinicalTrials.gov number, NCT05437263.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vleugels et al. (2026) studied this question.

synapsesocial.com/papers/69ccb55116edfba7beb87479https://doi.org/10.1056/nejmoa2503531
Ask AI
Helpful
Bookmark
Share
View Full Paper